EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction

Paschalis Karakasis iD, Panagiotis Theofilis iD, Panayotis K Vlachakis iD, Konstantinos Grigoriou, Dimitrios Patoulias iD, Antonios P Antoniadis iD, Nikolaos Fragakis iD

Pharmaceutics · 07.08.2025 · 17 (8) · 1028

DOI: 10.3390/pharmaceutics17081028 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 07.08.2025. Verfasst von Paschalis Karakasis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Hippokration General Hospital, Medical School, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Th…. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 297 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is a progressive, multifactorial disease driven by the interplay of lipid dysregulation, chronic inflammation, oxidative stress, and maladaptive vascular remodeling. Despite advances in systemic lipid-lowering and anti-inflammatory therapies, residual cardiovascular risk persists, highlighting the need for more precise interventions. Targeted drug delivery represents a transformative strategy, offering the potential to modulate key pathogenic processes within atherosclerotic plaques while minimizing systemic exposure and off-target effects. Recent innovations span a diverse array of platforms, including nanoparticles, liposomes, exosomes, polymeric carriers, and metal–organic frameworks (MOFs), engineered to engage distinct pathological features such as inflamed endothelium, dysfunctional macrophages, oxidative microenvironments, and aberrant lipid metabolism. Ligand-based, biomimetic, and stimuli-responsive delivery systems further enhance spatial and temporal precision. In parallel, advances in in-silico modeling and imaging-guided approaches are accelerating the rational design of multifunctional nanotherapeutics with theranostic capabilities. Beyond targeting lipids and inflammation, emerging strategies seek to modulate immune checkpoints, restore endothelial homeostasis, and reprogram plaque-resident macrophages. This review provides an integrated overview of the mechanistic underpinnings of atherogenesis and highlights state-of-the-art targeted delivery systems under preclinical and clinical investigation. By synthesizing recent advances, we aim to elucidate how precision-guided drug delivery is reshaping the therapeutic landscape of atherosclerosis and to chart future directions toward clinical translation and personalized vascular medicine.

Schlagwörter

Stichwörter der Autor:innen

atheromatous plaqueatherosclerosisendothelial dysfunctionmacrophage reprogrammingnanomedicinenanoparticlesprecision medicinetargeted drug deliverytheranostics

Autor:innen und Institutionen

  • Second Department of Cardiology, Hippokration General Hospital, Medical School, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece.
  • First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Pharmacology, University of Athens, 75 Mikras Asias Avenue, 11527 Goudi, Greece.
  • Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences Aristotle, University of Thessaloniki, 54124 Thesaloniki, Greece.

ORCID-Profile: Paschalis Karakasis, Panagiotis Theofilis, Panayotis K Vlachakis, Dimitrios Patoulias, Antonios P Antoniadis, Nikolaos Fragakis

Zitieren

APA

Karakasis, P., Theofilis, P., Vlachakis, P. K., Grigoriou, K., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2025). Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics, 17(8), 1028. https://doi.org/10.3390/pharmaceutics17081028

Vancouver

Karakasis P, Theofilis P, Vlachakis PK, Grigoriou K, Patoulias D, Antoniadis AP, et al. Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics. 2025;17(8):1028. doi:10.3390/pharmaceutics17081028

BibTeX
@article{Karakasis2025,
  author = {Karakasis, Paschalis and Theofilis, Panagiotis and Vlachakis, Panayotis K and Grigoriou, Konstantinos and Patoulias, Dimitrios and Antoniadis, Antonios P and Fragakis, Nikolaos},
  title = {Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {8},
  pages = {1028},
  doi = {10.3390/pharmaceutics17081028}
}
Kostenlos starten →